​

PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PTCT Stock Forecast

PTC Therapeutics (PTCT) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $84.50, with a high of $120.00 and a low of $50.00. This represents a 33.36% increase from the last price of $63.36.

$25 $44 $63 $82 $101 $120 High: $120 Avg: $84.5 Low: $50 Last Closed Price: $63.36

PTCT Stock Rating

PTC Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (61.54%), 8 Hold (30.77%), 2 Sell (7.69%), and 0 Strong Sell (0.00%).

Buy
Total 26 0 2 8 16 Strong Sell Sell Hold Buy Strong Buy

PTCT Price Target Upside V Benchmarks

TypeNameUpside
StockPTC Therapeutics33.36%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4613
Avg Price Target$95.00$98.17$84.92
Last Closing Price$63.36$63.36$63.36
Upside/Downside49.94%54.94%34.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 263641-14
Feb, 263741-15
Jan, 262751-15
Dec, 252751-15
Nov, 253751-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 23, 2026Morgan Stanley$92.00$70.6630.20%45.20%
Feb 23, 2026Eliana MerleBarclays$120.00$70.6669.83%89.39%
Feb 20, 2026Brian AbrahamsRBC Capital$82.00$67.9520.68%29.42%
Feb 20, 2026Wells Fargo$86.00$69.9023.03%35.73%
Jan 27, 2026Barclays$119.00$75.4957.64%87.82%
Jan 08, 2026Morgan Stanley$90.00$77.2416.52%42.05%
Dec 01, 2025RBC Capital$91.00$85.995.83%43.62%
Nov 05, 2025Goldman Sachs$50.00$71.79-30.35%-21.09%
Nov 05, 2025Tiago FauthWells Fargo$93.00$67.7237.33%46.78%
Nov 05, 2025Gena WangBarclays$68.00$67.720.41%7.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 23, 2026Morgan StanleyOverweightOverweighthold
Feb 23, 2026BarclaysOverweightOverweighthold
Feb 20, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 20, 2026RBC CapitalSector PerformSector Performhold
Jan 29, 2026Cowen & Co.HoldHoldhold
Jan 27, 2026BarclaysEqual-WeightOverweightupgrade
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 01, 2025RBC CapitalOutperformSector Performdowngrade
Nov 05, 2025Cowen & Co.HoldHoldhold
Nov 05, 2025Goldman SachsSellSellhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.43$-7.79$-8.37$-4.73$8.58---
Avg Forecast$-6.68$-6.96$-7.09$-4.52$-1.40$-1.63$-0.53$0.32
High Forecast$-5.48$-4.15$-5.97$-3.20$-0.57$1.00$1.54$0.62
Low Forecast$-7.72$-14.90$-9.02$-5.17$-2.36$-6.27$-3.09$0.22
Surprise %11.23%11.93%18.05%4.65%-712.86%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$538.59M$698.80M$937.82M$806.78M$1.73B---
Avg Forecast$524.98M$716.43M$943.98M$797.55M$726.66M$884.80M$1.09B$1.16B
High Forecast$587.90M$1.35B$945.10M$797.70M$778.11M$897.16M$1.12B$1.98B
Low Forecast$452.26M$494.03M$942.01M$797.40M$675.21M$872.44M$1.05B$879.21M
Surprise %2.59%-2.46%-0.65%1.16%138.16%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-523.90M$-559.02M$-626.60M$-363.30M$682.64M---
Avg Forecast$-436.99M$-398.38M$-626.60M$-313.22M$-46.36M$-145.50M$-63.54M$23.91M
High Forecast$-349.59M$-318.70M$-501.28M$-239.54M$-42.57M$74.52M$115.61M$46.13M
Low Forecast$-524.39M$-478.05M$-751.92M$-386.90M$-176.78M$-469.44M$-231.58M$16.44M
Surprise %19.89%40.32%-15.99%-1572.56%---

PTCT Forecast FAQ

Is PTC Therapeutics stock a buy?

PTC Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 8 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that PTC Therapeutics is a favorable investment for most analysts.

What is PTC Therapeutics's price target?

PTC Therapeutics's price target, set by 26 Wall Street analysts, averages $84.5 over the next 12 months. The price target range spans from $50 at the low end to $120 at the high end, suggesting a potential 33.36% change from the previous closing price of $63.36.

How does PTC Therapeutics stock forecast compare to its benchmarks?

PTC Therapeutics's stock forecast shows a 33.36% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for PTC Therapeutics over the past three months?

  • March 2026: 21.43% Strong Buy, 42.86% Buy, 28.57% Hold, 7.14% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 46.67% Buy, 26.67% Hold, 6.67% Sell, 0% Strong Sell.
  • January 2026: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 6.67% Sell, 0% Strong Sell.

What is PTC Therapeutics’s EPS forecast?

PTC Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.63, marking a -119.00% decrease from the reported $8.58 in 2025. Estimates for the following years are $-0.53 in 2027, and $0.32 in 2028.

What is PTC Therapeutics’s revenue forecast?

PTC Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $884.8M, reflecting a -48.87% decrease from the reported $1.73B in 2025. The forecast for 2027 is $1.09B, and $1.16B for 2028.

What is PTC Therapeutics’s net income forecast?

PTC Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-145M, representing a -121.31% decrease from the reported $682.64M in 2025. Projections indicate $-63.541M in 2027, and $23.91M in 2028.